Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial
Conclusions:
The maximum tolerated dose of nal-IRI was 50 mg/m2 every 2 weeks with TMZ 50 mg/m2/d. The dose-limiting toxicities were diarrhea and neutropenia. No activity was seen at interim analysis and the study was terminated.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Central Nervous System Source Type: research
More News: Anorexia | Brain | Cancer & Oncology | Eating Disorders & Weight Management | Nanotechnology | Neurology | Study | Temodar | Toxicology